Obesity or Overweight Clinical Trials

20 clinical trials for Obesity or Overweight across international registries, including 6 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes — RECRUITING · PHASE3
• A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes — RECRUITING · PHASE3
• Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study — RECRUITING · PHASE3
• Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight — RECRUITING · PHASE3
• Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH) — RECRUITING · PHASE3
• Study on Gastric Emptying Effect and Drug-Drug Interactions of GZR18 Injection — RECRUITING · PHASE1
• A Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or Overweight — NOT_YET_RECRUITING · PHASE2
• A Study Evaluating the Effect of Daily Oral RO7795081 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity — COMPLETED · PHASE2
• A Study in Participants With Obesity or Overweight With at Least One Weight-related Comorbidity — COMPLETED · PHASE2
• A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone — COMPLETED · PHASE2
• Study of Once-Daily Oral RGT001-075 Compared With Placebo in Adults With Obesity or Are Overweight With Weight-Related Health Conditions — COMPLETED · PHASE2
• A study investigating the safety of RO7795081 and the effect of RO7795081 on how the body processes different approved medications. RO7795081 is a new compound that may potentially be used in the treatment of type 2 diabetes and weight control — TERMINATED · PHASE1
• A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight — COMPLETED · PHASE3
• A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight — COMPLETED · PHASE3
• Comparison of the Effects of a Traditional Calorie-Restricted Diet and a Diet Incorporating Sirtuin-Based Elements on Body Weight, Body Composition, Nutritional Profile, and Antioxidant Potential: A Randomized Interventional Study — OTHER
• A Phase Ib Study of AZD5004 in Chinese Participants With Overweight/Obesity With or Without Type 2 Diabetes Mellitus — COMPLETED · PHASE1
• Effects of AZD5004 in Adults Who Are Living With Obesity or Overweight With at Least 1 Weight-related Comorbidity — COMPLETED · PHASE2
• A Study of IBI362 in Participants With Obesity or Overweight — COMPLETED · PHASE3
• A Research Study About Weight Loss and Treatment Patterns With the Use of Saxenda® in Adults in Real-life Settings in Switzerland — COMPLETED
• Obesity Treatment Using an Internet-delivered Intervention Based on the Diabetes Prevention Program in Mexican Adults — COMPLETED · NA

Refine this search